Nasdaq25d
Canaccord Genuity Initiates Coverage of Candel Therapeutics (CADL) with Buy Recommendation
The projected annual revenue for Candel Therapeutics is 25MM, an increase of 79,854.84%. The projected annual non-GAAP EPS is -0.90. Baker Bros. Advisors holds 2,982K shares representing 9.18% ...
Nasdaq25d
B of A Securities Initiates Coverage of Candel Therapeutics (CADL) with Buy Recommendation
Fintel reports that on February 7, 2025, B of A Securities initiated coverage of Candel Therapeutics (NasdaqGM:CADL) with a Buy recommendation. As of January 29, 2025, the average one-year price ...